# ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

> **NCT01366001** · PHASE1 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Cocaine Abuse

## Interventions

- **DRUG:** ALKS 33-BUP
- **DRUG:** ALKS 33
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01366001
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2012-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01366001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01366001, "ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01366001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*